Perspective Therapeutics announces first patient treated with PSV359

Perspective Therapeutics (CATX) announced that the first patient was treated with 212Pb PSV359 in a second cohort of the Company’s Phase 1/2a dose-finding trial to determine safety and preliminary anti-tumor activity of the radiopharmaceutical 212Pb PSV359 in patients with solid tumors that express fibroblast activation protein alpha. Patients are being selected for 212Pb PSV359 targeted alpha particle therapy by SPECT imaging with 212Pb PSV359. “Dosing the first patient in the second cohort marks an important step in advancing our evaluation of 212Pb PSV359 for cancers expressing FAP-alpha,” said Markus Puhlmann, Chief Medical Officer of Perspective. “FAP-alpha is found in a wide range of epithelial malignancies, including pancreatic cancer, colorectal cancer, and many sarcomas. Because of its multi-factorial biologic effects within the tumor microenvironment, it contributes to disease progression and negatively affects treatment response. These characteristics highlight the broad potential of PSV359 across multiple solid tumors. This study is helping us determine the optimal dose and indications to move forward, either as a monotherapy or in future combination strategies.”